BR0210153A - Composto, uso do mesmo, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, para o tratamento de doença do refluxo gastro-esofágico e de regurgitação em crianças, e para o tratamento de asma, hipercinesia, eructação, tosse, dor, vìcio de cocaìna, retirada de álcool, dependência de nicotina, soluços, ibs, dispepsia, êmese ou nocicepção, e, formulação farmacêutica - Google Patents

Composto, uso do mesmo, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, para o tratamento de doença do refluxo gastro-esofágico e de regurgitação em crianças, e para o tratamento de asma, hipercinesia, eructação, tosse, dor, vìcio de cocaìna, retirada de álcool, dependência de nicotina, soluços, ibs, dispepsia, êmese ou nocicepção, e, formulação farmacêutica

Info

Publication number
BR0210153A
BR0210153A BR0210153-0A BR0210153A BR0210153A BR 0210153 A BR0210153 A BR 0210153A BR 0210153 A BR0210153 A BR 0210153A BR 0210153 A BR0210153 A BR 0210153A
Authority
BR
Brazil
Prior art keywords
treatment
addiction
reflux disease
nociception
emesis
Prior art date
Application number
BR0210153-0A
Other languages
English (en)
Inventor
Kevin Fitzpatrick
William Geiss
Anders Lehmann
Gunnel Sunden
Sverker Von Unge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102056A external-priority patent/SE0102056D0/xx
Priority claimed from SE0104342A external-priority patent/SE0104342D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0210153A publication Critical patent/BR0210153A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"COMPOSTO, USO DO MESMO, MéTODOS PARA A INIBIçãO DE RELAXAMENTOS TRANSITóRIOS DO ESFìNCTER ESOFáGICO INFERIOR, PARA O TRATAMENTO DE DOENçA DO REFLUXO GASTRO-ESOFáGICO E DE REGURGITAçãO EM CRIANçAS, E PARA O TRATAMENTO DE ASMA, HIPERCINESIA, ERUCTAçãO, TOSSE, DOR, VìCIO DE COCAìNA, RETIRADA DE áLCOOL, DEPENDêNCIA DE NICOTINA, SOLUçOS, IBS, DISPEPSIA, êMESE OU NOCICEPçãO, E, FORMULAçãO FARMACêUTICA". Novos compostos de fórmula (I): em que R~ 1~, representa hidrogênio; R~ 2~ representa hidróxi, fluoro ou um grupo oxo; R~ 3~ representa hidrogênio; R~ 4~ representa hidrogênio; e seus sais, solvatos e estereoisómeros farmaceuticamente aceitáveis, com exceção do racemato de ácido (3-amino-2-hidroxipropil)sulfínico. Os compostos são úteis em terapia, especialmente para o tratamento de doença de refluxo. A invenção é também relacionada com processos para sua preparação, intermediários de dito processo e composições farmacêuticas contendo ditos compostos terapeuticamente ativos e ao uso de ditos compostos ativos em terapia.
BR0210153-0A 2001-06-08 2002-06-04 Composto, uso do mesmo, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, para o tratamento de doença do refluxo gastro-esofágico e de regurgitação em crianças, e para o tratamento de asma, hipercinesia, eructação, tosse, dor, vìcio de cocaìna, retirada de álcool, dependência de nicotina, soluços, ibs, dispepsia, êmese ou nocicepção, e, formulação farmacêutica BR0210153A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102056A SE0102056D0 (sv) 2001-06-08 2001-06-08 New Compounds
SE0104342A SE0104342D0 (sv) 2001-12-20 2001-12-20 New compounds
PCT/SE2002/001085 WO2002100823A1 (en) 2001-06-08 2002-06-04 New compounds useful in reflux disease

Publications (1)

Publication Number Publication Date
BR0210153A true BR0210153A (pt) 2004-06-08

Family

ID=26655485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210153-0A BR0210153A (pt) 2001-06-08 2002-06-04 Composto, uso do mesmo, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, para o tratamento de doença do refluxo gastro-esofágico e de regurgitação em crianças, e para o tratamento de asma, hipercinesia, eructação, tosse, dor, vìcio de cocaìna, retirada de álcool, dependência de nicotina, soluços, ibs, dispepsia, êmese ou nocicepção, e, formulação farmacêutica

Country Status (14)

Country Link
US (1) US6919379B2 (pt)
EP (1) EP1399419A1 (pt)
JP (1) JP2004529982A (pt)
KR (1) KR20040007658A (pt)
CN (1) CN1514825A (pt)
AR (1) AR033779A1 (pt)
AU (1) AU2002309420C1 (pt)
BR (1) BR0210153A (pt)
CA (1) CA2448518A1 (pt)
IL (1) IL158999A0 (pt)
MX (1) MXPA03011193A (pt)
NO (1) NO20035431D0 (pt)
NZ (1) NZ529920A (pt)
WO (1) WO2002100823A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060183800A1 (en) * 2004-11-12 2006-08-17 Xianqi Kong Methods and fluorinated compositions for treating amyloid-related diseases
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
DE3326545A1 (de) * 1983-07-22 1985-01-31 Ludwig Heumann & Co GmbH, 8500 Nürnberg Propan-2-ol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
AU594424B2 (en) 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5214063A (en) 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
MXPA03011193A (es) 2004-02-26
KR20040007658A (ko) 2004-01-24
EP1399419A1 (en) 2004-03-24
AU2002309420C1 (en) 2008-05-29
NZ529920A (en) 2005-08-26
IL158999A0 (en) 2004-05-12
AR033779A1 (es) 2004-01-07
JP2004529982A (ja) 2004-09-30
AU2002309420B2 (en) 2007-11-08
CA2448518A1 (en) 2002-12-19
US6919379B2 (en) 2005-07-19
NO20035431D0 (no) 2003-12-05
WO2002100823A1 (en) 2002-12-19
US20040152775A1 (en) 2004-08-05
CN1514825A (zh) 2004-07-21

Similar Documents

Publication Publication Date Title
BR0016253A (pt) Composto, uso de um composto, métodos para a inibição dos relaxamentos do esfìncter esofágico inferior transientes para o tratamento da doença do refluxo gastroesofágico, da regurgitação em bebês, de nocicepção, êmese. dispepsia, ibs, soluções, adicção em cocaìna, dor, tosse, eructação, asma relacionados ou não com gord, formulação farmacêutica, e, processo para a preparação de um composto
IL88239A (en) 4- (substituted- 2-benzocycloheptene -2- ylethenyl)- benzoic acid derivatives, their preparation and pharmaceutical compositions containing them
JPS62155205A (ja) 抗真菌性のマニキユア液
BR0016291A (pt) Composto, uso do mesmo, métodos para a inibição das relaxações do esfìncter esofágico inferior transientes, para o tratamento da doença do refluxo gastroesofágico, da regurgitação em bebês, de nocicepção, êmese, dispepsia, ibs, soluços, adicção de cocaìna, dor, tosse, eructação, asma relacionada ou não com gord, e, formulação farmacêutica
BR0210153A (pt) Composto, uso do mesmo, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, para o tratamento de doença do refluxo gastro-esofágico e de regurgitação em crianças, e para o tratamento de asma, hipercinesia, eructação, tosse, dor, vìcio de cocaìna, retirada de álcool, dependência de nicotina, soluços, ibs, dispepsia, êmese ou nocicepção, e, formulação farmacêutica
CA3032555C (en) Nicotine ion pair formulation neutralized with co2 and process therefor
MXPA04003192A (es) Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
AR039404A1 (es) Combinaciones de medicamentos que contienen compuestos heterociclicos y un agente anticolinergico. aerosol para su inhalacion
DK163185C (da) 1h-imidazol-1-ethanol og estere deraf og deres farmaceutisk acceptable syreadditionssalte til anvendelse som talgsyntesehaemmende midler samt farmaceutiske praeparater indeholdende saadanne forbindelser
BR9913102A (pt) Composto, produtos contento um composto, processo para preparação de um composto, formulação farmacêutica contento um composto, uso de um composto, processos para inibir a secreção de ácido gástrico, para o tratamento de doenças inflamatórias gastrintestinais e, para o tratamento ou profilaxia de condições que envolvam a infecção por helicobacter pylori da mucosa gástrica humana, e, formulação farmacêutica
DE68917937D1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
ES2045083T3 (es) Un procedimiento para preparar un compuesto quimico.
DK163182C (da) Dialkylaminoalkoxybenzylalkoholderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og fremgangsmaade til fremstilling deraf
DD207200A1 (de) Verfahren zur herstellung substituierter dibenzodiazepinone
MY133438A (en) Morpholinobenzamide salts
DE3867312D1 (de) Spiro (4,5) decanderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
JPWO2005007191A1 (ja) 医薬組成物
EP0301474A3 (en) New cysteine derivatives having expectorant activity
JPH07138139A (ja) 口腔用組成物
AU530930B2 (en) Pharmaceutical compositions and method of treating heart disease
SE8204693L (sv) Lekemedel med speciellt antiarrytmisk och understodjande verkan vid hjerthypoxi och forfarande for framstellning derav
GR3019970T3 (en) Pharmaceutical compositions for use in treating aids
IE790237L (en) Benzimidazol-2-ones.
DE3765124D1 (de) Neue stickstoffarylmethoxy-thiophenderivate und deren saeureadditionssalze,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE69008489D1 (de) Morpholinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.